Cabaletta Bio (CABA) Income from Continuing Operations (2018 - 2025)
Cabaletta Bio's (CABA) quarterly Income from Continuing Operations came in at 37002000.0 in Q4 2025, down 13.55% year-on-year from 42802526.52 in Q4 2024, and up 44.72% quarter-over-quarter from 66934000.0 in Q3 2025.
Cabaletta Bio (CABA) Income from Continuing Operations (2018 - 2025) Analysis & Trends
Cabaletta Bio's Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 37002000.0 for Q4 2025.
- On a quarterly basis, Income from Continuing Operations fell 13.55% year-over-year to 37002000.0 in Q4 2025; TTM through Dec 2025 was 194127000.0, a 9.4% increase from a year earlier, with the FY2025 full-year figure at 324060000.0, down 43.49% from the prior year.
- Income from Continuing Operations rose to 37002000.0 in Q4 2025 per CABA's latest filing, from 66934000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 13890367.0 in Q4 2021 and bottomed at 94812000.0 in Q1 2024.
- The 5-year median for Income from Continuing Operations is 33338500.0 (2023), against an average of 38079618.35.
- Across the five-year window, Income from Continuing Operations slumped 327.09% in 2023 and soared 56.62% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 13890367.0 in 2021, then sank by 33.92% to 18602000.0 in 2022, then dropped by 11.15% to 20677000.0 in 2023, then tumbled by 57.6% to 32586000.0 in 2024, then fell by 13.55% to 37002000.0 in 2025.
- Per Business Quant, the three latest CABA Income from Continuing Operations figures stand at 37002000.0 (Q4 2025), 66934000.0 (Q3 2025), and 49062000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Cabaletta Bio | 182.04 Mn | 182.04 Mn | - | -37.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -37.00 Mn |
| Sep 30, 2025 | -66.93 Mn |
| Jun 30, 2025 | -49.06 Mn |
| Mar 31, 2025 | -41.13 Mn |
| Dec 31, 2024 | -32.59 Mn |
| Sep 30, 2024 | -45.85 Mn |
| Jun 30, 2024 | -41.03 Mn |
| Mar 31, 2024 | -94.81 Mn |
| Dec 31, 2023 | -20.68 Mn |
| Sep 30, 2023 | -75.33 Mn |
| Jun 30, 2023 | -56.42 Mn |
| Mar 31, 2023 | -34.09 Mn |
| Dec 31, 2022 | -18.60 Mn |
| Sep 30, 2022 | -17.64 Mn |
| Jun 30, 2022 | -22.66 Mn |
| Mar 31, 2022 | -23.46 Mn |
| Dec 31, 2021 | -13.89 Mn |
| Sep 30, 2021 | -28.04 Mn |
| Jun 30, 2021 | -19.56 Mn |
| Mar 31, 2021 | -22.81 Mn |